SCHEMBL2127217

SCHEMBL2127217

NCC1(NC(=O)C(F)(F)F)CCN(C(=O)O)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27225337 0.83 ALDH1A1 (0.34)
SCHEMBL1586974 0.80 EPHX2 (0.43)
SCHEMBL5568218 0.77 CYP3A4 (0.32)
SCHEMBL5567244 0.76 HDAC2 (0.39)
SCHEMBL27189622 0.75 OPRM1 (0.34)
SCHEMBL18319191 0.73 ALDH1A1 (0.35)
Trifluoroacetic Acid SCHEMBL30019358 0.72 CPB2 (0.31)
SCHEMBL5567219 0.72 CYP2D6 (0.41)
SCHEMBL2334122 0.69 USP2 (0.31)
SCHEMBL476361 0.68 OPRL1 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2813227-A1 Compositions for treatment of cystic fibrosis and other chronic diseases Vertex Pharmaceuticals Incorporated (US) 2014-12-17 EP disclosed
EP-2444120-A1 Spirocyclic amiloride analogues as ENac blockers Novartis AG (CH) 2012-04-25 EP disclosed